{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "HKD", "exchange": "HKG", "shortName": "ZAI LAB", "longName": "Zai Lab Limited", "messageBoardId": "finmb_271123063", "exchangeTimezoneName": "Asia/Hong_Kong", "exchangeTimezoneShortName": "HKT", "gmtOffSetMilliseconds": 28800000, "market": "hk_market", "esgPopulated": false, "regularMarketChangePercent": -4.852685, "regularMarketPrice": 27.45, "marketState": "CLOSED", "firstTradeDateMilliseconds": 1601256600000, "priceHint": 3, "epsTrailingTwelveMonths": -3.4, "epsForward": -2.9, "epsCurrentYear": -10.81, "priceEpsCurrentYear": -2.5393155, "sharesOutstanding": 979086976, "bookValue": 10.889, "fiftyDayAverage": 27.705, "fiftyDayAverageChange": -0.25499916, "fiftyDayAverageChangePercent": -0.009204084, "twoHundredDayAverage": 29.1628, "twoHundredDayAverageChange": -1.7127991, "twoHundredDayAverageChangePercent": -0.058732327, "marketCap": 26875938816, "forwardPE": -9.465517, "priceToBook": 2.5208926, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -1.3999996, "regularMarketTime": 1683878916, "regularMarketDayHigh": 28.55, "regularMarketDayRange": "27.15 - 28.55", "regularMarketDayLow": 27.15, "regularMarketVolume": 1167600, "regularMarketPreviousClose": 28.85, "bid": 27.3, "ask": 27.45, "fullExchangeName": "HKSE", "financialCurrency": "USD", "regularMarketOpen": 28.55, "averageDailyVolume3Month": 2167086, "averageDailyVolume10Day": 855551, "fiftyTwoWeekLowChange": 10.530001, "fiftyTwoWeekLowChangePercent": 0.62234044, "fiftyTwoWeekRange": "16.92 - 44.0", "fiftyTwoWeekHighChange": -16.55, "fiftyTwoWeekHighChangePercent": -0.37613633, "fiftyTwoWeekLow": 16.92, "fiftyTwoWeekHigh": 44.0, "earningsTimestamp": 1683720000, "earningsTimestampStart": 1691452800, "earningsTimestampEnd": 1691971200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "9688.HK"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Jinchuang Plaza", "address2": "Building 1, Fourth Floor 4560 Jinke Road Pudong", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 21 6163 2588", "website": "https://www.zailaboratory.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-na\u00efve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.", "fullTimeEmployees": 2036, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ying  Du Ph.D.", "age": 56, "title": "Founder, Chairperson & CEO", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 1667101, "fmt": "1.67M", "longFmt": "1,667,101"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4758112, "fmt": "4.76M", "longFmt": "4,758,112"}}, {"maxAge": 1, "name": "Mr. Joshua L.  Smiley", "age": 52, "title": "Pres & COO", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 647109, "fmt": "647.11k", "longFmt": "647,109"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rafael G.  Amado M.D.", "age": 58, "title": "Pres and Head of Global Oncology R&D", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 477000, "fmt": "477k", "longFmt": "477,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ki Chul  Cho", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 748243, "fmt": "748.24k", "longFmt": "748,243"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Harald  Reinhart M.D.", "age": 70, "title": "Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases", "yearBorn": 1952, "fiscalYear": 2022, "totalPay": {"raw": 923330, "fmt": "923.33k", "longFmt": "923,330"}, "exercisedValue": {"raw": 68601, "fmt": "68.6k", "longFmt": "68,601"}, "unexercisedValue": {"raw": 1779, "fmt": "1.78k", "longFmt": "1,779"}}, {"maxAge": 1, "name": "Dr. Peter  Huang Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Frazor Titus  Edmondson III", "age": 56, "title": "Chief Legal Officer & Corp. Sec.", "yearBorn": 1966, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Ann E.  Beasley J.D.", "title": "Chief Compliance Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ning  Xu M.D.", "age": 57, "title": "Exec. VP & Head of Clinical Operations", "yearBorn": 1965, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jonathan J.  Wang MBA, Ph.D.", "age": 40, "title": "Chief Bus. Officer", "yearBorn": 1982, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}